Cortice Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02047214
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
🇺🇸Washington University, School of Medicine, Saint Louis, Missouri, United States
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01933815
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00553813
- Locations
- 🇪🇸
Hospital Madrid, Madrid, Spain
🇺🇸Desert Hematology Oncology Medical Group, Inc., Rancho Mirage,, California, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00479635
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
- Conditions
- NeoplasmsHodgkin's DiseaseNon-Hodgkin's Lymphoma
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2007-10-15
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00256191
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
Study of TPI 287 in Patients With Advanced Malignancies
- Conditions
- NeoplasmsNon-Hodgkin LymphomaHodgkin Disease
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00113724
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Georgetown University Medical Center/Lombardi Cancer Center, Washington, DC, District of Columbia, United States